Literature DB >> 25190121

The 90-day mortality after pancreatectomy for cancer is double the 30-day mortality: more than 20,000 resections from the national cancer data base.

Richard S Swanson1, Christopher M Pezzi, Katherine Mallin, Ashley M Loomis, David P Winchester.   

Abstract

BACKGROUND: Operative mortality traditionally has been defined as the rate within 30 days or during the initial hospitalization, and studies that established the volume-outcome relationship for pancreatectomy used similar definitions.
METHODS: Pancreatectomies reported to the National Cancer Data Base (NCDB) during 2007-2010 were examined for 30- and 90-day mortality. Unadjusted mortality rates were compared by type of resection, stage, comorbidities, and average annual hospital volume. Hierarchical logistic regression models generated risk-adjusted odds ratios for 30- and 90-day mortality.
RESULTS: After 21,482 pancreatectomies, the unadjusted 30-day mortality rate was 3.7 % (95 % confidence interval [CI] 3.4-3.9 %), which doubled at 90 days to 7.4 % (95 % CI 7.0-7.8). The unadjusted and risk-adjusted mortality rates were higher at 30 days with increasing age, increasing stage, male gender, lower income, low hospital volume, resections other than distal pancreatectomy, Medicare or Medicaid insurance coverage, residence in a Southern census division, history of prior cancer, and multiple comorbidities. The lowest-volume hospitals (<5 per year) performed 19 % of the pancreatectomies, with a risk-adjusted odds ratios for mortality that were 4.2 times higher (95 % CI 3.1-5.8) at 30 days and remained 1.9 times higher (95 % CI 1.5-2.3) at 30-90 days compared with hospitals that had high volumes (≥40 per year).
CONCLUSION: Mortality rates within 90 days after pancreatic resection are double those at 30 days. The volume-outcome relationship persists in the NCDB. Reporting mortality rates 90 days after pancreatectomy is important. Hospitals should be aware of their annual volume and mortality rates 30 and 90 days after pancreatectomy and should benchmark the use of high-volume hospitals.

Entities:  

Mesh:

Year:  2014        PMID: 25190121     DOI: 10.1245/s10434-014-4036-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  32 in total

1.  An Evaluation of Artificial Neural Networks in Predicting Pancreatic Cancer Survival.

Authors:  Steven Walczak; Vic Velanovich
Journal:  J Gastrointest Surg       Date:  2017-08-03       Impact factor: 3.452

2.  [Quality indicators for colon cancer surgery : Evidence-based development of a set of indicators for the outcome quality].

Authors:  J Hardt; H-J Buhr; C Klinger; S Benz; K Ludwig; J Kalff; S Post
Journal:  Chirurg       Date:  2018-01       Impact factor: 0.955

3.  Plectin-1 as a Biomarker of Malignant Progression in Intraductal Papillary Mucinous Neoplasms: A Multicenter Study.

Authors:  Maria Moris; David W Dawson; Jennifer Jiang; Jason Lewis; Aziza Nassar; Kenneth K Takeuchi; Anna R Lay; Qihui Zhai; Timothy R Donahue; Kimberly A Kelly; Howard C Crawford; Michael Wallace
Journal:  Pancreas       Date:  2016-10       Impact factor: 3.327

Review 4.  Minimally Invasive Pancreaticoduodenectomy: What is the Best "Choice"? A Systematic Review and Network Meta-analysis of Non-randomized Comparative Studies.

Authors:  Claudio Ricci; Riccardo Casadei; Giovanni Taffurelli; Carlo Alberto Pacilio; Marco Ricciardiello; Francesco Minni
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

5.  Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality.

Authors:  Jason W Denbo; Morgan L Bruno; Jordan M Cloyd; Laura Prakash; Jeffrey E Lee; Michael Kim; Christopher H Crane; Eugene J Koay; Sunil Krishnan; Prajnan Das; Bruce D Minsky; Gauri Varadhachary; Rachna Shroff; Robert Wolff; Milind Javle; Michael J Overman; David Fogelman; Thomas A Aloia; Jean-Nicolas Vauthey; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2016-10-11       Impact factor: 3.452

6.  Volume-outcome relationships in pancreatoduodenectomy for cancer.

Authors:  Lydia G M van der Geest; L Bengt van Rijssen; I Quintus Molenaar; Ignace H de Hingh; Bas Groot Koerkamp; Olivier R C Busch; Valery E P P Lemmens; Marc G H Besselink
Journal:  HPB (Oxford)       Date:  2016-02-11       Impact factor: 3.647

Review 7.  Comparative Effectiveness of Resection vs Surveillance for Pancreatic Branch Duct Intraductal Papillary Mucinous Neoplasms With Worrisome Features.

Authors:  Yinin Hu; Lily E. Johnston; Vanessa M. Shami; Todd W. Bauer; Reid B. Adams; George J. Stukenborg; Victor M. Zaydfudim
Journal:  JAMA Surg       Date:  2018-03-01       Impact factor: 14.766

8.  Locally advanced pancreatic duct adenocarcinoma: pancreatectomy with planned arterial resection based on axial arterial encasement.

Authors:  J Perinel; G Nappo; M El Bechwaty; T Walter; V Hervieu; P J Valette; P Feugier; M Adham
Journal:  Langenbecks Arch Surg       Date:  2016-07-30       Impact factor: 3.445

9.  Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer.

Authors:  Marcia Irene Canto; Tossapol Kerdsirichairat; Charles J Yeo; Ralph H Hruban; Eun Ji Shin; Jose Alejandro Almario; Amanda Blackford; Madeline Ford; Alison P Klein; Ammar A Javed; Anne Marie Lennon; Atif Zaheer; Ihab R Kamel; Elliot K Fishman; Richard Burkhart; Jin He; Martin Makary; Matthew J Weiss; Richard D Schulick; Michael G Goggins; Christopher L Wolfgang
Journal:  J Gastrointest Surg       Date:  2019-06-13       Impact factor: 3.452

10.  Mortality after pancreaticoduodenectomy: assessing early and late causes of patient death.

Authors:  Sowmya Narayanan; Allison N Martin; Florence E Turrentine; Todd W Bauer; Reid B Adams; Victor M Zaydfudim
Journal:  J Surg Res       Date:  2018-06-27       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.